DNA vs BIIB

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

DNA

44.2
AI Score
VS
DNA Wins

BIIB

38.4
AI Score

Investment Advisor Scores

DNA

44score
Recommendation
HOLD

BIIB

38score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric DNA BIIB Winner
Forward P/E 0 16.0772 Tie
PEG Ratio 0 3.383 Tie
Revenue Growth -28.6% 10.6% BIIB
Earnings Growth 0.0% -84.8% DNA
Tradestie Score 44.2/100 38.4/100 DNA
Profit Margin -192.0% 3.4% BIIB
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY DNA

Relative Price Performance (Last 90 Days)

DNA 1M: -11.3% · 3M: +50.7% BIIB 1M: +7.6% · 3M: +19.4%

Current Technical Phase

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 47

RSI (14): 47.0 · Price: $10.23

BIIB

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (6.2% over 20 days), RSI 57

RSI (14): 56.8 · Price: $250.48

Fundamentals Snapshot

Metric DNA BIIB
Market Cap — —
Forward P/E -3.5 15.4
Trailing P/E — 109.7
Revenue (TTM) — —
Revenue Growth -0.1% 0.1%
Gross Margin 0.7% 0.8%
Operating Margin -2.0% 0.2%
EPS -4.24 2.31
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, DNA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.